Naftopidil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naftopidil
Accession Number
DB12092
Type
Small Molecule
Groups
Investigational
Description

Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
R9PHW59SFN
CAS number
57149-07-2
Weight
Average: 392.499
Monoisotopic: 392.20999277
Chemical Formula
C24H28N2O3
InChI Key
HRRBJVNMSRJFHQ-UHFFFAOYSA-N
InChI
InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
IUPAC Name
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol
SMILES
COC1=CC=CC=C1N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Naftopidil.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Naftopidil.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Naftopidil.Experimental
AbciximabNaftopidil may increase the anticoagulant activities of Abciximab.Approved
AcebutololAcebutolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
AcemetacinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNaftopidil may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Acetylsalicylic acid.Approved, Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Naftopidil.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Naftopidil.Approved, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Naftopidil is combined with Aloxiprin.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Naftopidil.Approved, Withdrawn
AlprostadilAlprostadil may increase the antiplatelet activities of Naftopidil.Approved, Investigational
AlteplaseNaftopidil may increase the anticoagulant activities of Alteplase.Approved
AmbrisentanNaftopidil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNaftopidil may increase the hypotensive activities of Amifostine.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Aminosalicylic Acid.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Naftopidil.Approved
AmobarbitalThe metabolism of Naftopidil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Naftopidil.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Naftopidil.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Naftopidil.Approved, Investigational
AnagrelideNaftopidil may increase the anticoagulant activities of Anagrelide.Approved
AncrodNaftopidil may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Naftopidil.Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Naftopidil.Approved, Investigational
AnistreplaseNaftopidil may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanNaftopidil may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Naftopidil is combined with Apixaban.Approved
ArdeparinNaftopidil may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNaftopidil may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Naftopidil.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Naftopidil.Approved
AstaxanthinNaftopidil may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololAtenolol may increase the hypotensive activities of Naftopidil.Approved
AvanafilAvanafil may increase the antihypertensive activities of Naftopidil.Approved
AzelastineAzelastine may increase the antiplatelet activities of Naftopidil.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Naftopidil.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Naftopidil is combined with Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Naftopidil can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Naftopidil can be increased when combined with Barbital.Illicit
BarnidipineNaftopidil may increase the antihypertensive activities of Barnidipine.Approved
BatroxobinNaftopidil may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminNaftopidil may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinNaftopidil may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Naftopidil.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Naftopidil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Naftopidil.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Naftopidil.Approved, Investigational
BepridilBepridil may increase the hypotensive activities of Naftopidil.Approved, Withdrawn
BeraprostNaftopidil may increase the anticoagulant activities of Beraprost.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Naftopidil.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Naftopidil.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Naftopidil.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Naftopidil.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Naftopidil.Approved
BivalirudinNaftopidil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Naftopidil.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Naftopidil.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Naftopidil.Experimental
BretyliumBretylium may increase the hypotensive activities of Naftopidil.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Naftopidil.Approved
BrinaseNaftopidil may increase the anticoagulant activities of Brinase.Experimental
BrofaromineBrofaromine may increase the hypotensive activities of Naftopidil.Experimental
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Naftopidil.Investigational
BuflomedilNaftopidil may increase the antiplatelet activities of Buflomedil.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Naftopidil.Investigational
BupranololBupranolol may increase the hypotensive activities of Naftopidil.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Naftopidil.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Naftopidil.Approved
ButylphthalideNaftopidil may increase the antiplatelet activities of Butylphthalide.Investigational
CadralazineCadralazine may increase the hypotensive activities of Naftopidil.Experimental
CafedrineNaftopidil may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanNaftopidil may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Naftopidil.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Naftopidil.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Naftopidil.Experimental
CangrelorNaftopidil may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabNaftopidil may increase the anticoagulant activities of Caplacizumab.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Naftopidil.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Naftopidil.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Naftopidil is combined with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Naftopidil.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Naftopidil.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Naftopidil.Approved, Investigational
CaseinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Naftopidil.Approved
CeliprololCeliprolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
CertoparinNaftopidil may increase the anticoagulant activities of Certoparin.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Naftopidil.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Naftopidil.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Naftopidil.Approved
CicletanineNaftopidil may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Naftopidil.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Naftopidil.Approved
CilostazolNaftopidil may increase the anticoagulant activities of Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Naftopidil can be increased when it is combined with Cimetidine.Approved, Investigational
Citric AcidNaftopidil may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Naftopidil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Naftopidil.Approved
CloranololNaftopidil may increase the hypotensive activities of Cloranolol.Experimental
CloricromenNaftopidil may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneNaftopidil may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Naftopidil.Approved, Vet Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Naftopidil is combined with Collagenase clostridium histolyticum.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Naftopidil.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Naftopidil.Approved
CyclopenthiazideNaftopidil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Naftopidil.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Naftopidil.Approved
Dabigatran etexilateNaftopidil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNaftopidil may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNaftopidil may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNaftopidil may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Naftopidil.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Naftopidil.Approved, Investigational
DefibrotideNaftopidil may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelaprilNaftopidil may increase the hypotensive activities of Delapril.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Dersalazine.Investigational
DeserpidineNaftopidil may increase the hypotensive activities of Deserpidine.Approved
DesirudinNaftopidil may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseNaftopidil may increase the anticoagulant activities of Desmoteplase.Investigational
DextranNaftopidil may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Naftopidil.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Naftopidil.Vet Approved
DicoumarolNaftopidil may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Naftopidil.Investigational
DiflunisalThe risk or severity of adverse effects can be increased when Naftopidil is combined with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Naftopidil.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Naftopidil.Approved, Investigational
DiphenadioneNaftopidil may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleNaftopidil may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleNaftopidil may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DorzolamideDorzolamide may increase the hypotensive activities of Naftopidil.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Naftopidil.Approved
Drotrecogin alfaNaftopidil may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Naftopidil.Approved
Edetic AcidNaftopidil may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNaftopidil may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Naftopidil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Naftopidil.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Naftopidil.Approved
EndralazineEndralazine may increase the hypotensive activities of Naftopidil.Experimental
EnoxaparinNaftopidil may increase the anticoagulant activities of Enoxaparin.Approved
EpanololNaftopidil may increase the hypotensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Naftopidil.Approved, Investigational
EplivanserinNaftopidil may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineNaftopidil may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolNaftopidil may increase the anticoagulant activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Naftopidil.Approved
EptifibatideNaftopidil may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateNaftopidil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FelodipineFelodipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Naftopidil.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Naftopidil.Experimental
Ferulic acidNaftopidil may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinNaftopidil may increase the anticoagulant activities of Fibrinolysin.Investigational
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Naftopidil.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Naftopidil.Approved, Investigational
FluindioneNaftopidil may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Naftopidil.Experimental
FondaparinuxNaftopidil may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumNaftopidil may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Naftopidil.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Naftopidil.Approved, Investigational, Vet Approved
GabexateNaftopidil may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Naftopidil.Approved, Investigational
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Naftopidil.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Naftopidil.Approved, Investigational, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Naftopidil is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Naftopidil.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Naftopidil.Approved
GuanazodineNaftopidil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Naftopidil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Naftopidil.Approved, Investigational
GuanoclorNaftopidil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNaftopidil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNaftopidil may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Naftopidil.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Naftopidil.Approved, Withdrawn
HarmalineHarmaline may increase the hypotensive activities of Naftopidil.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Hemoglobin crosfumaril.Experimental
HeparinNaftopidil may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Naftopidil.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Naftopidil.Approved, Investigational
HexobarbitalThe metabolism of Naftopidil can be increased when combined with Hexobarbital.Approved
HigenamineNaftopidil may increase the anticoagulant activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Naftopidil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Naftopidil.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Naftopidil.Approved, Investigational
HydroxytyrosolNaftopidil may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Naftopidil.Approved
IbudilastIbudilast may increase the antiplatelet activities of Naftopidil.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Naftopidil.Approved, Investigational, Nutraceutical
IdraparinuxNaftopidil may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the antiplatelet activities of Naftopidil.Approved, Investigational, Withdrawn
IfetrobanNaftopidil may increase the antiplatelet activities of Ifetroban.Investigational
IloprostNaftopidil may increase the anticoagulant activities of Iloprost.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Naftopidil.Investigational
IndapamideIndapamide may increase the hypotensive activities of Naftopidil.Approved
IndenololIndenolol may increase the hypotensive activities of Naftopidil.Withdrawn
IndobufenNaftopidil may increase the anticoagulant activities of Indobufen.Investigational
IndoraminIndoramin may increase the hypotensive activities of Naftopidil.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Naftopidil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Naftopidil.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Naftopidil.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Naftopidil.Approved
IsradipineIsradipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Naftopidil.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Naftopidil.Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Naftopidil.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Naftopidil.Approved
LacidipineLacidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Naftopidil.Approved, Investigational
LepirudinNaftopidil may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
LetaxabanNaftopidil may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Naftopidil.Approved, Investigational
LinsidomineNaftopidil may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Naftopidil.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Naftopidil.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Naftopidil.Approved
MacitentanNaftopidil may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Naftopidil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MelagatranNaftopidil may increase the anticoagulant activities of Melagatran.Experimental
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Naftopidil.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Mesalazine.Approved
MethohexitalThe metabolism of Naftopidil can be increased when combined with Methohexital.Approved
MethoserpidineNaftopidil may increase the hypotensive activities of Methoserpidine.Experimental
Methyl salicylateThe risk or severity of adverse effects can be increased when Naftopidil is combined with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Naftopidil.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Naftopidil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Naftopidil.Approved, Investigational
MethylphenobarbitalThe metabolism of Naftopidil can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Naftopidil.Approved
MetolazoneMetolazone may increase the hypotensive activities of Naftopidil.Approved
MetoprololMetoprolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
MetyrosineNaftopidil may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Naftopidil.Experimental
MibefradilMibefradil may increase the hypotensive activities of Naftopidil.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Naftopidil.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Naftopidil.Approved, Investigational, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Naftopidil.Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Naftopidil.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Naftopidil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Naftopidil.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Naftopidil.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Naftopidil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Naftopidil.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Naftopidil.Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MuzolimineNaftopidil may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Naftopidil.Experimental
NadololNadolol may increase the hypotensive activities of Naftopidil.Approved
NadroparinNaftopidil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNaftopidil may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Naftopidil.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Naftopidil.Approved
NebivololNebivolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Naftopidil.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Naftopidil.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Naftopidil.Experimental
NiguldipineNiguldipine may increase the hypotensive activities of Naftopidil.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Naftopidil.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NimesulideNimesulide may increase the antiplatelet activities of Naftopidil.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Naftopidil.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Naftopidil is combined with Nitroaspirin.Investigational
NitroprussideNaftopidil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Naftopidil.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Naftopidil.Approved, Vet Approved
ObinutuzumabNaftopidil may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Naftopidil.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Naftopidil.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Naftopidil.Approved, Nutraceutical
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Naftopidil.Experimental
OtamixabanNaftopidil may increase the anticoagulant activities of Otamixaban.Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Naftopidil.Approved
OxprenololOxprenolol may increase the hypotensive activities of Naftopidil.Approved
OzagrelNaftopidil may increase the anticoagulant activities of Ozagrel.Investigational
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Naftopidil.Investigational
PargylinePargyline may increase the hypotensive activities of Naftopidil.Approved
ParnaparinNaftopidil may increase the anticoagulant activities of Parnaparin.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
Pentaerythritol TetranitrateNaftopidil may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Naftopidil.Approved, Investigational
PentobarbitalThe metabolism of Naftopidil can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Naftopidil.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Naftopidil.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Naftopidil.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Naftopidil.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Naftopidil.Approved
PhenindioneNaftopidil may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypotensive activities of Naftopidil.Withdrawn
PhenobarbitalThe metabolism of Naftopidil can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Naftopidil.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Naftopidil.Withdrawn
PhenprocoumonNaftopidil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolaminePhentolamine may increase the hypotensive activities of Naftopidil.Approved
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Naftopidil is combined with Phenyl aminosalicylate.Approved
PicotamideNaftopidil may increase the anticoagulant activities of Picotamide.Experimental
PinacidilPinacidil may increase the hypotensive activities of Naftopidil.Approved
PindololPindolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Naftopidil.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Naftopidil.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Naftopidil.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Naftopidil.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Naftopidil.Approved, Investigational, Vet Approved
PrasugrelNaftopidil may increase the anticoagulant activities of Prasugrel.Approved
PrazosinPrazosin may increase the hypotensive activities of Naftopidil.Approved
PrimidoneThe metabolism of Naftopidil can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Naftopidil.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
Protein CNaftopidil may increase the anticoagulant activities of Protein C.Approved
Protein S humanNaftopidil may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNaftopidil may increase the anticoagulant activities of Protocatechualdehyde.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Naftopidil.Experimental
QuinaprilQuinapril may increase the hypotensive activities of Naftopidil.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Naftopidil.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Naftopidil.Experimental
RamatrobanNaftopidil may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilRamipril may increase the hypotensive activities of Naftopidil.Approved
RasagilineRasagiline may increase the hypotensive activities of Naftopidil.Approved
RelcovaptanNaftopidil may increase the antiplatelet activities of Relcovaptan.Investigational
RemikirenRemikiren may increase the hypotensive activities of Naftopidil.Approved
RescinnamineNaftopidil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Naftopidil.Approved, Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Naftopidil.Approved, Experimental, Investigational
ReteplaseNaftopidil may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinNaftopidil may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Naftopidil.Approved
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Naftopidil.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Naftopidil.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Naftopidil.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Naftopidil.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Naftopidil.Approved, Investigational
RiociguatNaftopidil may increase the hypotensive activities of Riociguat.Approved
RituximabNaftopidil may increase the hypotensive activities of Rituximab.Approved
RivaroxabanNaftopidil may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneNaftopidil may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Naftopidil.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Naftopidil.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Salicylic acid.Approved, Investigational, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Naftopidil.Experimental
SarpogrelateNaftopidil may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseNaftopidil may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalThe metabolism of Naftopidil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Naftopidil.Approved, Investigational, Vet Approved
SelexipagNaftopidil may increase the anticoagulant activities of Selexipag.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Naftopidil.Approved, Investigational
SevofluraneSevoflurane may increase the antiplatelet activities of Naftopidil.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Naftopidil.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Naftopidil.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Naftopidil.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Naftopidil.Approved, Investigational
SitaxentanNaftopidil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Naftopidil.Approved
SRT501SRT501 may increase the antiplatelet activities of Naftopidil.Investigational
StreptokinaseNaftopidil may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Naftopidil.Approved
SulodexideNaftopidil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Naftopidil.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Naftopidil.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Naftopidil.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Naftopidil.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Naftopidil.Experimental, Investigational
TenecteplaseNaftopidil may increase the anticoagulant activities of Tenecteplase.Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Naftopidil.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Naftopidil.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Naftopidil.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Naftopidil.Approved, Investigational
TesmilifeneTesmilifene may increase the antiplatelet activities of Naftopidil.Investigational
TetrahydropalmatineNaftopidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineNaftopidil may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Naftopidil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Naftopidil can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Naftopidil.Approved
TiboloneTibolone may increase the hypotensive activities of Naftopidil.Approved, Investigational
TicagrelorNaftopidil may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineNaftopidil may increase the anticoagulant activities of Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Naftopidil.Withdrawn
TimololTimolol may increase the hypotensive activities of Naftopidil.Approved
TinzaparinNaftopidil may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolNaftopidil may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Naftopidil.Approved
TipranavirTipranavir may increase the antiplatelet activities of Naftopidil.Approved, Investigational
TirofibanNaftopidil may increase the anticoagulant activities of Tirofiban.Approved
TolazolineTolazoline may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Naftopidil.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Naftopidil.Approved, Investigational, Vet Approved
TolonidineNaftopidil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Naftopidil.Approved
TorasemideTorasemide may increase the hypotensive activities of Naftopidil.Approved
TositumomabThe risk or severity of adverse effects can be increased when Naftopidil is combined with Tositumomab.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Naftopidil.Approved
TranilastTranilast may increase the antiplatelet activities of Naftopidil.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Naftopidil.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Naftopidil.Approved
TravoprostTravoprost may increase the hypotensive activities of Naftopidil.Approved
TreprostinilNaftopidil may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
TriflusalNaftopidil may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Naftopidil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Naftopidil.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Naftopidil.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Naftopidil is combined with Trolamine salicylate.Approved
TroxerutinNaftopidil may increase the anticoagulant activities of Troxerutin.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Naftopidil.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Naftopidil.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Naftopidil.Investigational
UrokinaseNaftopidil may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Naftopidil.Approved
VincamineNaftopidil may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNaftopidil may increase the hypotensive activities of Vinpocetine.Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Naftopidil.Approved, Nutraceutical, Vet Approved
VorapaxarNaftopidil may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Naftopidil.Approved, Investigational
WarfarinNaftopidil may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNaftopidil may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XipamideNaftopidil may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Naftopidil.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Naftopidil.Approved, Investigational, Vet Approved
ZofenoprilNaftopidil may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4418
PubChem Substance
347828396
ChemSpider
4265
BindingDB
50773
ChEBI
31891
ChEMBL
CHEMBL142635
Wikipedia
Naftopidil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
3CompletedTreatmentDisorder of Urinary Stent1
3CompletedTreatmentUreter Stones1
3Unknown StatusTreatmentHyperplasia1
4CompletedTreatmentLower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia1
4Unknown StatusTreatmentRenal Stones / Ureter Calculi1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0699 mg/mLALOGPS
logP3.65ALOGPS
logP3.77ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)7.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.17 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity115.96 m3·mol-1ChemAxon
Polarizability44.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0940000000-0343a26091ec3a7f543c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0849000000-feac1b69e7ec5e9d12d5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-1940000000-2c5b43ec0ae8e30b33df

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Naphthalenes / Methoxyanilines / Aminophenyl ethers / Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Anisoles / N-alkylpiperazines / Alkyl aryl ethers
show 6 more
Substituents
N-arylpiperazine / Phenylpiperazine / Naphthalene / Aminophenyl ether / Methoxyaniline / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Aniline or substituted anilines
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:20 / Updated on May 02, 2018 00:15